Evaluation of antibodies to β2-glycoprotein 1 in the causation of coronary atherosclerosis as part of the antiphospholipid syndrome

Australian and New Zealand Journal of Medicine

Volumn 29, Issue 6, 1999, Pages 789-793

  Limaye, V ^a   Beltrame, J ^a   Cook, R ^b   Gillis, D ^b   Pile, K ^a,c  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Anticardiolipin antibodies; Antiphospholipid syndrome; Coronary artery disease; 2 glycoprotein 1

Indexed keywords

ANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; CHOLESTEROL; TRIACYLGLYCEROL; AUTOANTIBODY; GLYCOPROTEIN; IMMUNOGLOBULIN G;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; BLOOD; CHI SQUARE DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; CHI-SQUARE DISTRIBUTION; CORONARY ARTERIOSCLEROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0033233113     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1999.tb00781.x     Document Type: Article

References (14)

1. 1. Nasonov EL, Noeva EA, Kovalev Vlu, Dragnev AG, Lopaeva OV, Ruda Mla. Cardiolipin antibodies in patients with myocardial infarction and unstable angina pectoris. Kardiologia 1992; 32: 32-4.
2. 2. Yilmaz E, Adalet K, Yilmaz G et al. Importance of serum anticardiolipin antibody levels in coronary heart disease. Clin Cardiol 1994; 17: 117-21.
3. 3. Ferlazzo B, Bonanno D, Quattrocchi P, Paino AM, Arrigo F. Connections between ischaemic heart disease and anticardiolipin antibody positivity. Minerva Cardioangiol 1993; 41: 113-7.
4. 4. Karpov IuA, Nasonov EL, Vil'chinskaia Mlu et al. The manifestations of IHD and the status of the coronary arteries in patients with antiphospholipid syndrome. Tarapevticheskii Archiv 1995; 67: 27-31.
5. 5. Koike T, Tsutsumi K, Ichikawa K, Matsuura E. Antibodies to ß2GP1 and clinical significance. Proceedings of The Australian Rheumatology Association 40th Annual Scientific Conference, May 1997. R71, 105.
6. 6. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996; 75: 721-4.
7. 7. Galli M, Comfurius P, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor. Lancet 1990; 335: 1544-7.
8. 8. Pierangeli SS, Harris EN, Davis SA, DeLorenzo G. ß2-glycoprotein 1 (ß2GP1) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies. Br J Haematol 1992; 82: 565-70.
9. 9. Roubey RAS, Pratt CW, Buyon JP et al. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon ß2-glycoprotein 1. J Clin Invest 1992; 90: 1100-4.
10. 10. Vaarala O, Manttari M, Manninen V et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-7.
11. 11. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280.
12. 12. Lopes-Virella M, Virella G. Immunological and microbial factors in the pathogenesis of atherosclerosis. Clin Immunol Immunopathol 1985; 37: 377-86.
13. 13. Saikku P, Leinonen M, Mattila K. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-6.
14. 14. Vaarala O, Palasvo T, Kleemola M, Kimmo A. Anticardiolipin responses to acute infections. Clin Immunol Immunopathol 1986; 65: 495-8.